Castle Biosciences (CSTL) Stock Price, News & Analysis

Company Overview

Castle Biosciences, Inc. (NASDAQ:CSTL) is a molecular diagnostics company focused on developing and commercializing proprietary tests that help guide treatment decisions for patients with skin cancer and other dermatologic conditions. Since its founding, the company has leveraged genomic science and rigorous clinical studies to create assays that stratify disease risk, inform prognosis and enable more personalized care pathways. Castle Biosciences is headquartered in Friendswood, Texas, and operates under Clinical Laboratory Improvement Amendments (CLIA) certification to ensure the highest standards of laboratory quality and regulatory compliance.

The company’s core offerings include DecisionDx® tests, which utilize gene expression profiling to assess the probability of disease progression or recurrence. DecisionDx-Melanoma aids dermatologists and oncologists in evaluating the metastatic risk of cutaneous melanoma, while DecisionDx-Ductal Carcinoma In Situ (DCIS) supports treatment planning for early-stage breast cancer. Castle Biosciences also offers DecisionDx-SCC and DecisionDx-GIST assays to inform management of cutaneous squamous cell carcinoma and gastrointestinal stromal tumors, respectively. Each test is backed by peer-reviewed publications and ongoing clinical collaboration to refine risk stratification models.

In addition to its U.S. operations, Castle Biosciences has expanded service capabilities through partnerships with international laboratories and academic medical centers, aiming to broaden patient access to its diagnostic technologies. The company invests in research and development to advance molecular insights, and it maintains an in-house bioinformatics team that continuously enhances algorithm performance. Educational programs and digital tools are provided to healthcare providers to support the integration of genomic data into routine clinical practice.

Leadership at Castle Biosciences is anchored by President and Chief Executive Officer Scott D. Difrancesco, who brings more than two decades of experience in molecular diagnostics and life sciences commercialization. The executive team includes seasoned professionals in clinical operations, regulatory affairs and health economics, all committed to driving innovation and expanding the company’s footprint in precision medicine. Castle Biosciences continues to collaborate with key opinion leaders and healthcare organizations to validate its tests and demonstrate their value in improving patient outcomes.

Key Stats

• Today's Range: $19.68 to $20.26
• 50-Day Range: $15.80 to $20.42
• 52-Week Range: $15.45 to $35.84
• Volume: 282,935 shs
• Average Volume: 421,815 shs
• Market Capitalization: $572.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Buy

Castle Biosciences Stock Analysis - MarketRank™

Castle Biosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 394th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Castle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Castle Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Castle Biosciences are expected to decrease in the coming year, from $0.44 to ($1.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Castle Biosciences is -104.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Castle Biosciences is -104.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Castle Biosciences has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.63% of the float of Castle Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Castle Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Castle Biosciences has recently decreased by 0.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Castle Biosciences does not currently pay a dividend.

Dividend Growth

Castle Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.63% of the float of Castle Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Castle Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Castle Biosciences has recently decreased by 0.79%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.70

News Sentiment

Castle Biosciences has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Castle Biosciences this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,599.00 in company stock.

Percentage Held by Insiders

Only 6.50% of the stock of Castle Biosciences is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CSTL Stock Analysis - Frequently Asked Questions

How have CSTL shares performed this year?

Castle Biosciences' stock was trading at $26.65 at the start of the year. Since then, CSTL shares have decreased by 25.4% and is now trading at $19.8690.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) issued its earnings results on Monday, May, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.12. The company earned $87.99 million during the quarter, compared to the consensus estimate of $80.40 million. Castle Biosciences had a positive trailing twelve-month return on equity of 3.41% and a negative net margin of 1.46%.
Read the conference call transcript.

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Castle Biosciences' major shareholders?

Top institutional investors of Castle Biosciences include Harbor Capital Advisors Inc. (0.07%) and First Bank & Trust (0.07%). Insiders that own company stock include Kristen M Oelschlager, Derek J Maetzold, Tobin W Juvenal, Frank Stokes, Ellen Goldberg, Tiffany Olson and Daniel Bradbury.
View institutional ownership trends.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CSTL
• CIK: 1447362
• Web: castlebiosciences.com
• Phone: (866) 788-9007
• Fax: N/A
• Employees: 540
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Castle Biosciences: $37.00
• High Price Target: $41.00
• Low Price Target: $30.00
• Potential Upside/Downside: +86.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 45.16
• P/E Growth: N/A
• Net Income: $18.25 million
• Net Margins: -1.46%
• Pretax Margin: -0.64%
• Return on Equity: 3.41%
• Return on Assets: 2.95%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 9.37
• Quick Ratio: 9.19

Sales & Book Value

• Annual Sales: $347.08 million
• Price / Sales: 1.65
• Cash Flow: $0.99 per share
• Price / Cash Flow: 20.08
• Book Value: $16.28 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 28,872,000
• Free Float: 26,995,000
• Market Cap: $573.66 million
• Optionable: Optionable
• Beta: 1.10